glp-1 lower cholesterol Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism Beyond the Cardiovascular Effects of

Sleep Deprivation: Effects on Weight Loss and Weight Loss Maintenance

Treatment adherence is improving: persistence improved from ~40% for those starting treatment in 2023 to 63% for those beginning in early 2024 (one-year continuation)

Although the genetic effect sizes we detected are modest, it is likely that additional data will reveal further associations and increase the predictive utility of genetics in this context

Some people naturally produce less GLP-1 or have a weaker GLP-1 response

The infrastructure is now being built: the CMS-0057-F rule mandates FHIR-based PA APIs by January 2027, AHIP pledges are driving operational improvements since January 2026, and the Medicare GLP-1 Bridge demonstration starting July 2026 will test centralized electronic PA at unprecedented scale

Our physicians offer medically supervised options including POTENTWave (GAINSWAVE alternative) and POTENTShot (P-Shot alternative) for men